Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2751 Carcinoma, Non-Small-Cell Lung 2243 Prostatic Neoplasms 1414 Colorectal Neoplasms 1277 Neoplasms 1253 Multiple Myeloma 1081 Lung Neoplasms 1044 Neoplasm Metastasis 989 Leukemia, Myeloid, Acute 972 Lymphoma 894 Melanoma 861 Pancreatic Neoplasms 813 Ovarian Neoplasms 802 Carcinoma, Hepatocellular 775 Stomach Neoplasms 747 Recurrence 745 Leukemia 733 Lymphoma, Non-Hodgkin 681 Leukemia, Lymphocytic, Chronic, B-Cell 662 Lymphoma, Large B-Cell, Diffuse 612 Squamous Cell Carcinoma of Head and Neck 608 Precursor Cell Lymphoblastic Leukemia-Lymphoma 603 Head and Neck Neoplasms 594 Brain Neoplasms 591 Carcinoma, Renal Cell 579 Glioblastoma 569 Rectal Neoplasms 558 Myelodysplastic Syndromes 520 Sarcoma 519 Lymphoma, Follicular 511

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡